Question · asked by 1 review
Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis: Health‐related quality of life ‐ not reported
- Population
- people with cancer with VTE receiving secondary prophylaxis
- Intervention
- Idraparinux secondary prophylaxis
- Comparison
- vitamin K antagonist secondary prophylaxis
- Outcome
- Health‐related quality of life ‐ not reported
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis Health‐related quality of life – not reported · people with cancer with VTE receiving secondary prophylaxis The review found no eligible studies for this question. Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer (2018) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.